3F8 antibody

a murine IgG3 antibody against GD2, a ganglioside expressed in many tumor systems

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

1.	Neuroblastoma 03/01/2015 - "After achieving first remission (n = 163), primary refractory disease (n = 102), or second remission (n = 95), children with stage 4 neuroblastoma received anti-GD2 3F8 antibody immunotherapy. " 05/01/1991 - "To verify that the technique would work in vivo, measurements were made of human neuroblastoma tumors in rats which had been injected with I-124 labeled 3F8 antibody. " 07/01/2003 - "During the period of this study (1995-1999), MSKCC patients with high-risk neuroblastoma received the N7 protocol (dose-intensive chemotherapy, immunotherapy with the anti-G(D2) 3F8 antibody, targeted radiotherapy using 131I-3F8, local radiotherapy) if they had assessable disease, or 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by 13-cis-retinoic acid if they were in remission after treatment elsewhere. "
2.	Neoplasms (Cancer) 05/01/1991 - "To verify that the technique would work in vivo, measurements were made of human neuroblastoma tumors in rats which had been injected with I-124 labeled 3F8 antibody. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2022 - "Our results support further assessment of GD2 using the 3F8 antibody as a predictive and prognostic biomarker in breast cancer."

1.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
2.	Isotretinoin (Accutane)
3.	Biomarkers (Surrogate Marker)